Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorbald van Hall

Showing results (101-110 of 120) with videos related to

Pageof 12
Sort By:
Cancer Cell|May 17, 2024
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacyMarit J van Elsas, Jim Middelburg, Camilla Labrie, et al.
Blood|July 27, 2021
Improved Sézary cell detection and novel insights into immunophenotypic and molecular heterogeneity in Sézary syndromeSafa Najidh, Cornelis P Tensen, Alita J van der Sluijs-Gelling, et al.
Plos One|November 11, 2014
Limited density of an antigen presented by RMA-S cells requires B7-1/CD28 signaling to enhance T-cell immunity at the effector phaseXiao-Lin Li, Marjolein Sluijter, Elien M Doorduijn, et al.
Cancer Immunology Research|January 9, 2024
Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based ImmunotherapiesChristianne Groeneveldt, Priscilla Kinderman, Lisa Griffioen, et al.
Gut|January 25, 2022
Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical modelSumit Kumar, Mark J A Schoonderwoerd, Jessie S Kroonen, et al.
Cell|December 4, 2018
NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer VaccinesNadine van Montfoort, Linda Borst, Michael J Korrer, et al.
Nature Communications|January 3, 2024
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumorsJim Middelburg, Marjolein Sluijter, Gaby Schaap, et al.
European Journal of Immunology|July 10, 2013
Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activationRodney A Rosalia, Esther D Quakkelaar, Anke Redeker, et al.
Communications Biology|November 13, 2025
Pyroglutamation of cell surface proteins CD47 and TRP1 by glutaminyl cyclase modulates therapeutic antibody bindingAnneloes van der Plas-van Duijn, Levi M T Winkelman, Claire Lensen, et al.
Journal for Immunotherapy of Cancer|September 3, 2020
Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapyElham Beyranvand Nejad, Camilla Labrie, Ziena Abdulrahman, et al.
Pageof 12

Showing results (101-110 of 120) with videos related to

Sort By:
Pageof 12
Cancer Cell|May 17, 2024
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacyMarit J van Elsas, Jim Middelburg, Camilla Labrie, et al.
Blood|July 27, 2021
Improved Sézary cell detection and novel insights into immunophenotypic and molecular heterogeneity in Sézary syndromeSafa Najidh, Cornelis P Tensen, Alita J van der Sluijs-Gelling, et al.
Plos One|November 11, 2014
Limited density of an antigen presented by RMA-S cells requires B7-1/CD28 signaling to enhance T-cell immunity at the effector phaseXiao-Lin Li, Marjolein Sluijter, Elien M Doorduijn, et al.
Cancer Immunology Research|January 9, 2024
Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based ImmunotherapiesChristianne Groeneveldt, Priscilla Kinderman, Lisa Griffioen, et al.
Gut|January 25, 2022
Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical modelSumit Kumar, Mark J A Schoonderwoerd, Jessie S Kroonen, et al.
Cell|December 4, 2018
NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer VaccinesNadine van Montfoort, Linda Borst, Michael J Korrer, et al.
Nature Communications|January 3, 2024
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumorsJim Middelburg, Marjolein Sluijter, Gaby Schaap, et al.
European Journal of Immunology|July 10, 2013
Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activationRodney A Rosalia, Esther D Quakkelaar, Anke Redeker, et al.
Communications Biology|November 13, 2025
Pyroglutamation of cell surface proteins CD47 and TRP1 by glutaminyl cyclase modulates therapeutic antibody bindingAnneloes van der Plas-van Duijn, Levi M T Winkelman, Claire Lensen, et al.
Journal for Immunotherapy of Cancer|September 3, 2020
Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapyElham Beyranvand Nejad, Camilla Labrie, Ziena Abdulrahman, et al.
Pageof 12